Eli Lilly stops trial of brain cancer drug


brain cancer BOSTON, Dec 21 (Reuters) - Eli Lilly & Co. (LLY.N) said on Thursday that it has stopped a trial of its experimental brain cancer drug after a monitoring committee determined the treatment would probably prove no more effective than chemotherapy in delaying progression of the disease.

Lilly said an interim analysis of data from a late-stage, or Phase III, study suggested the drug, enzastaurin, would not stave off an aggressive and recurrent form of brain cancer known as recurrent glioblastoma any better than chemotherapy.

The company said it will continue enrolling patients in a late-stage trial to evaluate enzastaurin as a potential treatment for non-Hodgkin's lymphoma. It will also continue mid-stage trials of the drug in other cancers, such as breast, colon, lung, ovarian and prostate.

source - Reuters 


Previous entry: Anti-Cancer 'Smart Bomb' Homes in on Deadly Tumors

Next entry: Quit Smoking if Pancreatic Cancer Runs in the Family

Find recent content on the main index or look in the archives to find all content.